BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 19638466)

  • 1. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
    Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
    Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
    Benetti A; Berenzi A; Gambarotti M; Garrafa E; Gelati M; Dessy E; Portolani N; Piardi T; Giulini SM; Caruso A; Invernici G; Parati EA; Nicosia R; Alessandri G
    Cancer Res; 2008 Oct; 68(20):8626-34. PubMed ID: 18922939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor endothelial cells join the resistance.
    Dudley AC; Klagsbrun M
    Clin Cancer Res; 2009 Aug; 15(15):4787-9. PubMed ID: 19638456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated tumor endothelial cells maintain specific character during long-term culture.
    Matsuda K; Ohga N; Hida Y; Muraki C; Tsuchiya K; Kurosu T; Akino T; Shih SC; Totsuka Y; Klagsbrun M; Shindoh M; Hida K
    Biochem Biophys Res Commun; 2010 Apr; 394(4):947-54. PubMed ID: 20302845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
    World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.
    Tentori L; Vergati M; Muzi A; Levati L; Ruffini F; Forini O; Vernole P; Lacal PM; Graziani G
    Int J Oncol; 2005 Aug; 27(2):525-35. PubMed ID: 16010436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phenotypic and functional characteristics of endothelial cells derived from human liver cancer].
    Wu LQ; Zhang WJ; Ye LY; Yang ZH; Lou JN
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):419-23. PubMed ID: 17974273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
    Kuczynski EA; Kerbel RS
    Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
    J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.